SAN DIEGO, Sept. 9, 2021 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that Jay Hagan, President and Chief
Executive Officer of Regulus, will present at the H.C. Wainwright
23rd Annual Global Investment Conference: An on-demand
webcast presentation will be available on Monday, September 13, 2021 at 7:00 a.m. ET.
A webcast of the presentation will be available under "Events
and Presentations" through the investor relations section of the
Company's website at www.regulusrx.com. A replay of the webcast
will be archived for 30 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate headquarters in
San Diego, CA.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding the Company's expected cash
runway and statements associated with the Company's RGLS4326
program, including the potential sufficiency of the data required
to recommence clinical studies for extended duration dosing, the
timing of the Company's interactions with FDA regarding the
clinical hold, the expected timing for reporting topline data, and
the timing and future occurrence of other preclinical and clinical
activities. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, the risk that feedback from
the FDA may be negative or may not be provided when we expect,
risks associated with our need for additional capital. In addition,
while Regulus expects the COVID-19 pandemic to adversely affect its
business operations and financial results, the extent of the impact
on Regulus' ability to achieve its preclinical and clinical
development objectives and the value of and market for its common
stock, will depend on future developments that are highly uncertain
and cannot be predicted with confidence at this time, such as the
ultimate duration of the pandemic, travel restrictions,
quarantines, social distancing and business closure requirements in
the U.S. and in other countries, and the effectiveness of actions
taken globally to contain and treat the disease. These and
other risks are described in additional detail in Regulus' filings
with the Securities and Exchange Commission, including under the
"Risk Factors" heading of Regulus most recently quarterly report on
Form 10-Q. All forward-looking statements contained in this
press release speak only as of the date on which they were made.
Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301372990.html
SOURCE Regulus Therapeutics Inc.